This article first appeared on GuruFocus.

Bioventus Inc (NASDAQ:BVS) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $138.20 million, and the earnings are expected to come in at $0.03 per share. The full-year 2025 revenue is expected to be $566.73 million, and the earnings are expected to be $0.26 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 5 Warning Signs with BVS.

Is BVS fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for Bioventus Inc (NASDAQ:BVS) have increased from $565.33 million to $566.73 million for the full year 2025 and from $600.73 million to $607.67 million for 2026 over the past 90 days. Earnings estimates have declined from $0.42 per share to $0.26 per share for the full year 2025 and from $0.55 per share to $0.49 per share for 2026 over the past 90 days.

In the previous quarter of 2025-06-30, Bioventus Inc's (NASDAQ:BVS) actual revenue was $147.66 million, which beat analysts' revenue expectations of $146.09 million by 1.08%. Bioventus Inc's (NASDAQ:BVS) actual earnings were $0.11 per share, which met analysts' earnings expectations. After releasing the results, Bioventus Inc (NASDAQ:BVS) was up by 18.73% in one day.

Based on the one-year price targets offered by 3 analysts, the average target price for Bioventus Inc (NASDAQ:BVS) is $14.67, with a high estimate of $15.00 and a low estimate of $14.00. The average target implies an upside of 123.92% from the current price of $6.55.

Based on GuruFocus estimates, the estimated GF Value for Bioventus Inc (NASDAQ:BVS) in one year is $5.87, suggesting a downside of -10.38% from the current price of $6.55.

Based on the consensus recommendation from 3 brokerage firms, Bioventus Inc's (NASDAQ:BVS) average brokerage recommendation is currently 2.0, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.